These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 36017491)

  • 1. YT521-B homology domain family proteins as N6-methyladenosine readers in tumors.
    Yang H; Chiang C; Luo Q; Chen C; Huang J; Zhu L; Zheng D
    Front Genet; 2022; 13():934223. PubMed ID: 36017491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms.
    Chen L; Gao Y; Xu S; Yuan J; Wang M; Li T; Gong J
    Front Immunol; 2023; 14():1162607. PubMed ID: 36999016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting m
    Zhang W; Wu T; Zhang Y; Kang W; Du C; You Q; Chen X; Jiang Z
    Bioorg Med Chem; 2023 Jul; 90():117373. PubMed ID: 37329678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers.
    Dai XY; Shi L; Li Z; Yang HY; Wei JF; Ding Q
    Front Oncol; 2021; 11():635329. PubMed ID: 33928028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the structure, physiological function, and role in cancer of m6A readers-YTH domain-containing proteins.
    Liao J; Wei Y; Liang J; Wen J; Chen X; Zhang B; Chu L
    Cell Death Discov; 2022 Mar; 8(1):137. PubMed ID: 35351856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy.
    Zhang Z; Liu F; Chen W; Liao Z; Zhang W; Zhang B; Liang H; Chu L; Zhang Z
    Exp Hematol Oncol; 2022 May; 11(1):30. PubMed ID: 35590394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the conservation and diversification of the molecular functions of YTHDF proteins.
    Flores-Téllez D; Tankmar MD; von Bülow S; Chen J; Lindorff-Larsen K; Brodersen P; Arribas-Hernández L
    PLoS Genet; 2023 Oct; 19(10):e1010980. PubMed ID: 37816028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
    Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of gene expression by YTH domain family (YTHDF) proteins in human physiology and pathology.
    Kisan A; Chhabra R
    J Cell Physiol; 2023 Jan; 238(1):5-31. PubMed ID: 36326110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-methyladenosine (m6A) as a regulator of carcinogenesis and drug resistance by targeting epithelial-mesenchymal transition and cancer stem cells.
    Wang C; Danli Ma ; Yu H; Zhuo Z; Ye Z
    Heliyon; 2023 Mar; 9(3):e14001. PubMed ID: 36915498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
    Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis B Virus X Protein Expression Is Tightly Regulated by N6-Methyladenosine Modification of Its mRNA.
    Kim GW; Siddiqui A
    J Virol; 2022 Feb; 96(4):e0165521. PubMed ID: 34851655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YTH Domain Proteins: A Family of m
    Xu Y; Zhang W; Shen F; Yang X; Liu H; Dai S; Sun X; Huang J; Guo Q
    Front Oncol; 2021; 11():629560. PubMed ID: 33692959
    [No Abstract]   [Full Text] [Related]  

  • 14. Link Between m6A Modification and Cancers.
    Liu ZX; Li LM; Sun HL; Liu SM
    Front Bioeng Biotechnol; 2018; 6():89. PubMed ID: 30062093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of RNA N6-methyladenosine in Cancer progression.
    Wang T; Kong S; Tao M; Ju S
    Mol Cancer; 2020 May; 19(1):88. PubMed ID: 32398132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
    Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
    Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer.
    Liu Q
    Front Genet; 2021; 12():825109. PubMed ID: 35087575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction.
    Chen J; Fang X; Zhong P; Song Z; Hu X
    RNA Biol; 2019 Aug; 16(8):991-1000. PubMed ID: 31107151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Function and evolution of RNA N6-methyladenosine modification.
    Zhu ZM; Huo FC; Pei DS
    Int J Biol Sci; 2020; 16(11):1929-1940. PubMed ID: 32398960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N6-Methyladenosine Modification and Its Role in mRNA Metabolism and Gastrointestinal Tract Disease.
    Cai T; Atteh LL; Zhang X; Huang C; Bai M; Ma H; Zhang C; Fu W; Gao L; Lin Y; Meng W
    Front Surg; 2022; 9():819335. PubMed ID: 35155557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.